Sign In
Buy HTBX
$2.38
+0 (+0%)
At Close: Aug 17, 2022
Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today
07:00am, Tuesday, 03'rd May 2022
DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing first-in-cla
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics
08:00am, Wednesday, 20'th Apr 2022
Elusys becomes wholly-owned biodefense subsidiary of NightHawk
Key Corporate Updates Announced Via Livestream Event from Manhattan, Kansas, available for replay at Nighthawkbio.com Key Corporate Updates Announced Via Livestream Event from Manhattan, Kansas, avail
DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to m
Heat Biologics' Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility
08:30am, Monday, 18'th Apr 2022
500,000+ square foot facility to support commercial-scale biomanufacturing
Heat Biologics' Announces Planned Investor and Media Livestream Event to Discuss Latest Developments
12:35pm, Thursday, 14'th Apr 2022
DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to m
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
08:00am, Friday, 25'th Mar 2022
New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and other cellular products New 3-D process desig
Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company
12:30pm, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
Burel to support anthrax and RapidVax™ biodefense initiatives as a platform for rapid response to known and unknown biological threats Burel to support anthrax and RapidVax™ biodefense initiatives
Burel to support anthrax and RapidVax™ biodefense initiatives as a platform for rapid response to known and unknown biological threats Burel to support anthrax and RapidVax™ biodefense initiatives
Heat Biologics reports 2021 revenue $2.1M, consensus $2.11M
01:06pm, Monday, 14'th Mar 2022 Seeking Alpha
Heat Biologics (HTBX) has presented favorable survival data at The American Association of Cancer Research of HS-110 in combination with checkpoint inhibitors for the treatment…
Heat Biologics to move to NYSE from Nasdaq
09:34pm, Wednesday, 02'nd Feb 2022 Seeking Alpha
Heat Biologics (HTBX) said it plans to change its listing to the NYSE American stock exchange from from the Nasdaq Capital Market.Heat expects to begin trading on NYSE under its
Heat Biologics Announces Planned Transfer to the NYSE American
09:05pm, Wednesday, 02'nd Feb 2022 GlobeNewswire Inc.
DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modula
Heat Biologics Announces Planned Transfer to the NYSE American
04:05pm, Wednesday, 02'nd Feb 2022
DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate
Heat Biologics rises 10% as Elusys finalizes HHS contract for anthrax antitoxin Anthim
08:33pm, Monday, 31'st Jan 2022 Seeking Alpha
Elusys Therapeutics, which is being acquired by Heat Biologics <>, said it finalized a contract with the U.S
Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services
12:30pm, Monday, 31'st Jan 2022 GlobeNewswire Inc.
Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023
